Merck KGaA, the German science and technology group, has agreed to acquire Bio-Techne Corporation for roughly $11.3 billion, paying $73 per share in cash, a premium of about 24% over the Minneapolis company’s prior close. It is Merck’s largest acquisition since it bought Sigma-Aldrich for $17 billion in 2014, and the first major deal under new chief executive Kai Beckmann. After a stretch in which tools companies traded at deflated multiples, the move is a statement: scale in the infrastructure of biology is once again worth paying up for.
Why Merck is reaching for Bio-Techne
Merck runs three business sectors, healthcare, electronics, and life science, and life science has become its strategic center of gravity. That unit already sells laboratory reagents, bioprocessing equipment, and contract manufacturing to drugmakers worldwide. What it has historically lacked is depth in the high-margin biological content at the very front of research: the proteins, antibodies, and analytical platforms scientists reach for before a drug program even exists.
Bio-Techne fills exactly that gap. Merck’s life science chief noted that it brings a catalogue of about 6,000 proteins and 425,000 antibodies, a breadth Merck called a meaningful advantage for customers. The deal is also pitched at Merck’s process-solutions business, extending its reach into higher-value reagents, analytics, and the cell and gene therapy workflows that are among the fastest-growing corners of biomanufacturing. Merck expects the transaction to be immediately accretive to sales growth and to its EBITDA margin after closing, with earnings accretion by the third year.
The needs of our customers are becoming increasingly complex. Researchers are generating deeper biological insights. New therapeutic modalities are emerging, and the path from discovery to manufacturing requires greater integration than ever before. That is why Bio-Techne is such a strong fit.
Kai Beckmann/Merck KGaA
What Bio-Techne actually does
For readers outside the lab, Bio-Techne supplies the raw biological materials and measurement tools that make experiments possible. To grow a particular type of cell, study a disease, or test whether a drug candidate hits its target, researchers need standardized, reliable inputs, and Bio-Techne makes many of them, the consumables and platforms that drug discovery, cell and gene therapy, and precision-medicine programs depend on every day.
Its core is recombinant proteins, lab-made versions of the cytokines and growth factors that tell cells how to behave, alongside antibodies and immunoassay kits that detect specific molecules in a sample. Through its ProteinSimple line it sells automated instruments that turn manual protein analysis into a repeatable workflow, and its RNAscope technology lets scientists see exactly where genes switch on inside a slice of tissue, central to spatial biology and diagnostics. The economics matter as much as the science: reagents and kits are consumed and reordered, and instruments pull proprietary consumables behind them, producing recurring revenue far stickier than one-off equipment sales, precisely what makes Bio-Techne attractive to a larger owner.
The consolidation wave behind the deal
Merck is not acting in isolation. The life-science tools sector has been consolidating for years, with Thermo Fisher, Danaher, and others using acquisitions to capture more of the spend that flows through every lab and biomanufacturing plant. The logic is consistent: whoever supplies the most complete, integrated workflow, from first reagent to final-fill manufacturing, can lock in customers, raise switching costs, and harvest recurring revenue across the arc of drug development.
Several forces push buyers in the same direction. Large pharmaceutical companies face a wave of patent expirations and are spending aggressively to refresh pipelines, keeping demand high for the underlying infrastructure. The shift toward complex modalities, cell and gene therapies, RNA-based drugs, antibody-drug conjugates, has made specialized reagents and process technologies more valuable, because these therapies are harder to make.
The increasingly scarce resource is not capital but differentiated, scalable assets: a company that owns validated assay libraries, a deep antibody catalogue, and proprietary instrument platforms holds a hard-to-replicate position. Biomanufacturers, wary of supply-chain fragility for critical biological inputs, increasingly want to own that supply rather than depend on third parties, making a complete, one-stop catalogue a selling point in itself.
Who wins, who watches
For pharmaceutical customers, a combined Merck–Bio-Techne could offer real convenience: a single supplier spanning research reagents, analytical instruments, and bioprocessing, with fewer vendors to manage. For biotech companies and academic researchers, the picture is mixed, balancing integrated, well-supported products against the fear that fewer suppliers means less leverage on price. For Bio-Techne’s investors, the 24% premium delivers a clear near-term return, sharpened by the activist pressure that had built on the company to sell. For Merck’s shareholders, the verdict rests on execution, whether it can turn an expensive acquisition into the durable, higher-growth franchise it has promised.
What the deal signals is unambiguous. After a fallow stretch, appetite for scale in the picks-and-shovels of biology has returned, and the companies that supply the field, rather than the drugs themselves, are once again prized strategic assets. Merck has bet substantially that owning more of that infrastructure is the right move for the next decade of drug discovery. The science behind the wager is sound; the question, as ever in large acquisitions, is whether integration can match ambition.
Read more biotech insights on OncoDaily Biotech.
Written by: Semiramida Nina Markosyan, Editor, OncoDaily Canada